Helix BioPharma (DB:HBP0) - Stock Price, News & Analysis

HBP0 Stock Overview

Operates as an immune-oncology company in Canada.

HBP0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Shares are highly illiquid

+ 3 more risks

Helix BioPharma Corp. Competitors

Medigene

XTRA:MDG1

€31.6m

4SC

DB:VSC

€58.0m

2invest

XTRA:2INV

€60.4m

Heidelberg Pharma

XTRA:HPHA

€112.3m

Price History & Performance

Summary of all time highs, changes and price drops for Helix BioPharma
Historical stock prices
Current Share Price	CA$0.78
52 Week High	CA$0.87
52 Week Low	CA$0.72
Beta	-0.84
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-80.48%
Change since IPO	-88.06%

Recent updates

Shareholder Returns

	HBP0	DE Biotechs	DE Market
7D	-7.1%	2.6%	4.5%
1Y	n/a	-16.4%	13.4%

Return vs Industry: Insufficient data to determine how HBP0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how HBP0 performed against the German Market.

Price Volatility

Is HBP0's price volatile compared to industry and market?
HBP0 volatility
HBP0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: HBP0 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HBP0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	9	Jacek Antas	www.helixbiopharma.com

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Helix BioPharma Corp. Fundamentals Summary

How do Helix BioPharma's earnings and revenue compare to its market cap?
HBP0 fundamental statistics
Market cap	€38.00m
Earnings (TTM)	-€4.07m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-9.3x

P/E Ratio

Is HBP0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HBP0 income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$6.14m
Earnings	-CA$6.14m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did HBP0 perform over the long term?

See historical performance and comparison

Helix BioPharma DB:HBP0 Stock Report